Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell lymphomas.

NCT Number	NCT06176027
Lead Sponsor	Navy General Hospital, Beijing Collaborators: Chinese PLA General Hospital
Conditions	Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas
Enrollment	52 participants
Start Date	2024-10-01
Primary Completion	2028-09-01 (estimated)
Study Completion	2030-09-01 (estimated)
Updated on ClinicalTrials.gov	2024-10-29